Drugs / LIV-GAMMA SN Inj. 10%
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05566990 | Jul 2019 → Jun 2021 | autoimmune thrombocytopenia | SK Plasma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LIV-GAMMA SN Inj. 10% | “LIV-GAMMA SN Inj. 10% is administered intravenously at a dose of 1 g/kg daily for 2 consecutive days to patients with primary immune thrombocytopenia.” NCT05566990 ↗ |
| Route | Intravenous | “administered intravenously” NCT05566990 ↗ |